Analyst Price Targets — EWTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 10, 2026 1:49 pm | Martin Auster | Raymond James | $46.00 | $29.67 | StreetInsider | Raymond James Reiterates Strong Buy Rating on Edgewise Therapeutics (EWTX): "we expect investor interest to grow" |
| February 26, 2026 9:02 pm | Cory Kasimov | Evercore ISI | $45.00 | $29.66 | StreetInsider | Edgewise Therapeutics (EWTX) PT Raised to $45 at Evercore ISI |
| February 26, 2026 2:50 pm | James Condulis | Stifel Nicolaus | $25.00 | $29.83 | StreetInsider | Edgewise Therapeutics (EWTX) PT Raised to $25 at Stifel |
| September 24, 2025 8:17 pm | — | Goldman Sachs | $20.00 | $16.59 | TheFly | Goldman Sachs assigns Neutral rating to Edgewise Therapeutics |
| March 7, 2025 11:49 am | — | Scotiabank | $50.00 | $28.01 | TheFly | Edgewise Therapeutics initiated with an Outperform at Scotiabank |
| December 5, 2024 6:02 pm | Srikripa Devarakonda | Truist Financial | $50.00 | $31.57 | StreetInsider | Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX), 'have reasons to believe that EWTX's study is not the study in question' |
| October 11, 2024 7:57 am | Yasmeen Rahimi | Piper Sandler | $51.00 | $30.46 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Edgewise Therapeutics (EWTX) |
| September 20, 2024 6:24 am | Leonid Timashev | RBC Capital | $42.00 | $29.50 | StreetInsider | Edgewise Therapeutics (EWTX) PT Raised to $42 at RBC Capital |
| September 19, 2024 2:50 pm | Joseph Schwartz | Leerink Partners | $42.00 | $29.50 | StreetInsider | Edgewise Therapeutics (EWTX) PT Raised to $42 at Leerink Partners |
| July 1, 2024 7:17 am | Yasmeen Rahimi | Piper Sandler | $48.00 | $18.01 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Edgewise Therapeutics (EWTX) |
Latest News for EWTX
Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) shares hit a new 52-week high on Tuesday. The stock traded as high as $34.00 and last traded at $32.83, with a volume of 577238 shares traded. The stock had previously closed at $33.33. Wall Street Analysts Forecast Growth Several equities research analysts have recently weighed
Shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) have been given an average rating of "Moderate Buy" by the ten research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have assigned a buy recommendation
SG Americas Securities LLC raised its position in shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX) by 797.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 88,723 shares of the company's stock after acquiring an additional 78,842 shares during the period.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) CMO Joanne Donovan sold 28,662 shares of the business's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $32.31, for a total value of $926,069.22. The sale was disclosed in a document filed with the Securities and
BOULDER, Colo., April 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on March 31, 2026, Edgewise granted inducement stock options to purchase a total of 72,000 shares of Edgewise's common stock to 4 new…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EWTX.
U.S. House Trading
No House trades found for EWTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.